TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The only requirement for including a day in the study will be that all the procedures performed in that specific day have been previously performed in our hospital at least 5 times a year for each of the last three years. This rule will encompass the vast majority of the performed vascular procedures in our facility. Setting the threshold at a minimum of 5 cases per year is essential to assure that some data will be available to calculate the expected length of the case with either the traditional or the predictive modeling system. If a case is performed in a day when the scheduling imprecision is supposed to be calculated using the PMS but modeling data do not exist, then the anticipated length of this case will be calculated using the historic means.~* Surgery cancellation after the first case will not disqualify that day from inclusion in the study. If the cancellation occurs in the last case of the sequence for the specific day then no particular intervention will be taken. The anticipated end of the surgical day will reset to the end of the last case that took place, and all the imprecision calculations will be performed as described below. If the cancellation occurs in one of the intermediate cases, then the end of the operative day will reset to reflect the removal of the cancelled case.~Exclusion Criteria:~A day will be excluded from the study when any of the following occur (based on historical data the investigators anticipate 10-15% of the operative days to meet the exclusion criteria):~* Only one or no cases have been scheduled for the entire operative day~* An emergency case is added as first case, or in between the scheduled cases.~* The operative day falls during a major holiday week (Thanksgiving, Christmas, New Year). The schedule during these time periods tends to be fragmented, cancellation rates are high, and cases are frequently performed with back-up teams only. All these factors may distort the findings.~* There is an unusual case in the schedule that does not meet the minimum requirement of 5 previous operations on a yearly basis for the last three years.~* The first case of the day is cancelled

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Historical means method (Type: ACTIVE_COMPARATOR): Operative time will be predicted using historical service means. Schedule will be constructed using this time
- Predictive Modeling System (PMS) (Type: EXPERIMENTAL): Operative time will be predicted using a regression model. Schedule will be constructed using this time

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease.~2. Relatively stable airway obstruction with post FEV1\< 80% predicted normal and post FEV1/FVC \<70%.~3. Male or female patients, 40 years of age or older.~4. Smoking history of more than 10 pack years.~Exclusion criteria:~1. Significant disease other than COPD~2. Clinically relevant abnormal lab values.~3. History of asthma.~4. Diagnosis of thyrotoxicosis~5. Diagnosis of paroxysmal tachycardia~6. History of myocardial infarction within 1 year of screening visit~7. Unstable or life-threatening cardiac arrhythmia.~8. Hospitalization for heart failure within the past year.~9. Known active tuberculosis.~10. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~11. History of life-threatening pulmonary obstruction.~12. History of cystic fibrosis.~13. Clinically evident bronchiectasis.~14. History of significant alcohol or drug abuse.~15. Thoracotomy with pulmonary resection~16. Oral ß-adrenergics.~17. Oral corticosteroid medication at unstable doses~18. Regular use of daytime oxygen therapy for more than one hour per day~19. Pulmonary rehabilitation program in the six weeks prior to the screening visit~20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit~21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA~22. Pregnant or nursing women.~23. Women of childbearing potential not using a highly effective method of birth control~24. Patients who are unable to comply with pulmonary medication restrictions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium+olodaterol low dose FDC (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium+olodaterol high dose FDC (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- olodaterol (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- tiotropium low dose (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- tiotropium high dose (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with OSA treated by nCPAP but still complaining with EDS~* ESS score \> or = 12~Exclusion Criteria:~* patient suffering from insomnia without OSA~* co-existing narcolepsy~* patient with sleep debt not due to OSA~* acute or chronic severe disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BF2.649 (Type: EXPERIMENTAL): BF2.649 capsules dosed at 5mg, 10 mg, 20mg
- Placebo (Type: PLACEBO_COMPARATOR): Capsules of Placebo containing lactose with low, medium and high dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* • Cases (PLWHIV + COVID-19)~  1. Any gender~ 2. At least 18 years of age~ 3. Documented HIV-1 infection~ 4. Confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021~     * Controls (COVID-19)~  <!-- -->~  1. Any gender~ 2. At least 18 years of age~ 3. No documented HIV-1 infection~ 4. Confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021~ 5. Meet the matching criteria~For comparing PLWHIV \& COVID-19 versus HIV seronegative COVID-19 patients, a 1:1 matching will be performed according to the following criteria:~* Age (+/- 5 years)~* Sex~* Ethnicity (where available)~* Month of COVID-19 diagnosis (+/- 2 months)~* COVID-19 diagnosis inpatient OR~* COVID-19 diagnosis outpatient (ambulatory)~* Controls (PLWHIV)~  1. Any gender~ 2. At least 18 years of age~ 3. Documented HIV-1 infection~ 4. No evidence of SARS-CoV-2 infection~ 5. Meet the matching criteria~For comparing PLWHIV \& COVID-19 versus PLWHIV without COVID-19, a 1:2 matching for similar risk of acquiring COVID-19 will be performed according to the following criteria:~* Age (+/- 5 years)~* Sex~* Ethnicity (where available)~Exclusion Criteria~For cases (PLWHIV + COVID-19) and for COVID-19 only controls:~* COVID-19 diagnosed based on clinical criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PLWHIV with COVID-19 cases (Type: None): Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
- PLWHIV without COVID-19 controls (Type: None): Patients at least 18 years of age with documented HIV-1 infection.
- HIV seronegative patients with COVID-19 controls (Type: None): Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age≥18 years old, male or female, signed Informed Consent Form (ICF).~2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~3. Histologically or cytologically confirmed ES-SCLC~4. No prior systemic treatment for ES-SCLC~5. Adequate hematologic and end organ function~Key Exclusion Criteria:~1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis;~2. Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;~3. Was administered a live vaccine ≤ 4 weeks before randomization;~4. Active autoimmune diseases or history of autoimmune diseases that may relapse~5. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before randomization;~6. With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;~7. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to randomization, including but not limited to tuberculosis infection;~8. Participant with untreated hepatitis B virus (HBV)/hepatitis C virus (HCV), or a known history of HIV infection;~9. Participants with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized at the time of randomization;~10. Clinically significant pericardial effusion, or Clinically uncontrolled pleural effusion~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tislelizumab plus etoposide and platinum (Type: EXPERIMENTAL): None
- Placebo plus etoposide and platinum (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 to 80 years inclusive at the time of informed consent~* Subjects must have non-malignant chronic pain treated with opioids and must have opioid-induced constipation (OIC)~* Subjects must be treated with a stable opioid regimen at a total daily dose on average of ≥ 30 mg equivalents of oral morphine sulfate~* Subjects must not be currently using laxatives or must be willing to discontinue laxative use at Screening and must be willing to use only the rescue laxatives provided throughout the study duration~* Subjects must meet opioid-induced constipation criteria based on the Bowel Movement and Constipation Assessment (BMCA) Diary~Exclusion Criteria:~* Evidence of significant structural abnormalities of the gastrointestinal (GI) tract~* Evidence of active medical diseases affecting bowel transit~* History or presence of pelvic disorders that may be a cause of constipation~* Surgery (except for minor procedures) within 60 days of Screening~* History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g., mechanical GI obstruction)~* Subjects who have never taken laxatives for the treatment of OIC~* History of active treatment for cancer within the last 2 years (except for basal cell or squamous cell carcinoma of the skin that have been successfully resected) or tamoxifen \[Nolvadex®\] and raloxifene \[Evista®\] when being used for prevention of breast cancer~* Current use of any prohibited medication including opioid antagonists, partial agonists, or mixed agonists/antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naldemedine (Type: EXPERIMENTAL): Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Arterial pH and Total Body Nitrogen Balances in APD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women from any ethnic/racial group \< 65 years.~2. Treatment with CPD for 6 months and current treatment with APD for at least one month.~3. Hemoglobin of at least 11.0 g/dl.~4. Stable dose of erythropoietin treatment for at least the preceding three months.~5. Subjects with normal nutritional status to mild malnutrition:~   1. Serum albumin \> 3.3 g/dl~  2. Relative body weight of 90-120% of the NHANES II median body weight for a given height, age range, gender and frame size.~  3. A normalized protein equivalent of total nitrogen appearance (nPNA) \> 0.80 g/kg actual body weight/day at the time of screening.~6. D/P Cr between 0.48 and 0.81 on the PET performed at the time of the screen.~7. Total (renal + peritoneal) weekly Kt/V urea \> 1.70 and creatinine clearance \> 50 L/wk/1.73 m2.~8. No evidence of primary or secondary (viz., ischemic, neuropathic) myopathy~Exclusion Criteria:~1. History of active cancer other than basal cell carcinoma.~2. Symptomatic severe ischemic heart disease, uncontrolled severe dysrhythmias, uncontrolled congestive heart failure, poorly controlled hypertension, severe musculoskeletal disease, arthritis or amputation of the lower extremities.~3. Insulin requiring diabetes mellitus.~4. Patients who received L-carnitine or anabolic hormones (other than erythropoietin) within the previous 6 months.~5. Use of CaCO3 as phosphate binder.~6. Severe lung or liver disease, uncontrolled asthma, active vasculitis.~7. Severe chronic infection or any other acute or chronic inflammatory or catabolic illnesses (e.g., active tuberculosis, AIDS, osteomyelitis).~8. Psychosis, inability to give informed consent, evidence that patient will not comply with study protocol.~9. Alcohol or other recreational drug abuse.~10. Pregnancy (rare in CPD patients).~11. Patients who are physically and/or psychologically incapable of undergoing the protocol.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low normal pH (arterial pH 7.36-7.38) (Type: ACTIVE_COMPARATOR): Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
- High Normal pH (arterial pH 7.44-7.46) (Type: ACTIVE_COMPARATOR): High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have at least 10 teeth~* Subjects must have the need for a dental extraction under general anesthesia (for behavioral reasons)~* Subjects will be recruited regardless of the extent and severity of their dental and/or periodontal disease~Exclusion Criteria:~* Age under 18 years~* Body weight under 40 kg~* Receipt of antibiotics in the previous 3 months~* Routine use of oral antiseptics~* A history of allergy or intolerance to amoxicillin~* A history of allergy or intolerance to chlorhexidine~* A history of allergy or intolerance to amoxicillin-clavulanate~* Any type of congenital or acquired immunodeficiency~* Any known risk factor for bacterial endocarditis~* Any known risk factor for prolonged bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Receiving no prophylaxis
- Amoxicillin (Type: ACTIVE_COMPARATOR): Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
- Amoxicillin-Potassium Clavulanate (Type: EXPERIMENTAL): Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
- Chlorhexidine (CHX) (Type: ACTIVE_COMPARATOR): Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
- Amoxicillin-Potassium Clavulanate-CHX (Type: EXPERIMENTAL): Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Part A:~* Overtly healthy males or females, as determined by medical history and physical examination~* Female participants not of child-bearing potential~Part B:~* Have a clinical diagnosis of idiopathic Parkinson's disease for at least 1 year and on stable medication for at least 4 weeks~Part A and B~* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures~* Have given written informed consent~* Have a body mass index (BMI) of 18.0 to 29.9 kilograms per square meter (kg/m²)~Exclusion Criteria:~* Have participated, in the last 30 days, in a clinical trial involving an investigational product~* Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; or constituting a risk when taking the study medication; or interfering with the interpretation of study data

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LY3154207 (Type: EXPERIMENTAL): LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching LY3154207 administered once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the arm~* Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the extremities or trunk~Exclusion Criteria:~* Location of the treatment area~  * within 5 cm of an incompletely healed wound~ * within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)~* Prior treatment with ingenol mebutate gel on the treatment area~* Lesions in the treatment areas that have:~  * atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous horns) and/or~ * recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 43204 (Type: EXPERIMENTAL): Open-label, dose-escalation, 2-day treatment
- LEO 43204 Dose 0.1% (Type: EXPERIMENTAL): LEO 43204 dose 0.1% once daily for two consecutive days
- LEO 43204 Dose 0.075% (Type: EXPERIMENTAL): LEO 43204 dose 0.075% once daily for two days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for two days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete